Fritextsökning
Innehållstyper
-
Meet ZEISS at ELRIG Advances in Cell-based Screening 2026
Reserve your spot now.
-
Medicon Village breakfast seminar: ISO 10993-1 in practice
Don't miss our breakfast seminar at Medicon Village on May 28th: ISO 10993-1 in practice - connecting biological evaluation to your technical documentation.
-
Important notification for IVDR Class C device manufacturers
Deadline for application is quickly approaching; 26 May 2026.
-
ISO 20417 has been updated – what device manufacturers should consider
The new edition of ISO 20417 has been published, further clarifying expectations for information supplied with medical devices. Although not yet harmonized, the...
-
Internal audits based on ISO 13485 for medtech organizations
Are you ready to turn your internal audits into real improvements? Internal auditing isn’t just about compliance—it’s a strategic tool for driving development a...
-
FDA leaders seek to scrap two-study requirement
A single pivotal study may be sufficient to secure approval for a new medicine in the United States. That is the message delivered by FDA Commissioner Marty Mak...
-
Networking event in Denmark: Sponsor Oversight in Clinical Trials
We are excited to invite clinical trial professionals to a networking event to connect and discuss best practices, challenges and adaptive strategies in documen...
-
“Ozempic babies” – myth or reality?
Have weight-loss drugs such as Ozempic led to a rise in unplanned pregnancies? Life Science Sweden takes a closer look.
-
Supporting Investigator Initiated Clinical Studies—From Start to Finish
Many important clinical studies start with researchers – not pharmaceutical companies. In investigator initiated studies, pharmaceutical companies often support...
-
Are you prepared for the updated ISO 10993 1:2025?
The latest edition of ISO 10993-1 reinforces the integration of biological evaluation with risk management, introduces updated approaches to exposure assessment...
-
Acne medication may be the solution when hair starts falling out
A treatment originally developed for acne has shown remarkable Phase III results in a completely different area: male-pattern hair loss.
-
Anna Törner: ”Drug prices – an important driver of innovation”
We live under the illusion that no price is too high when it comes to health, but that simply isn’t true, writes Anna Törner.
-
First injectable cancer medicine for home use receives green light
Johnson & Johnson has announced that its blockbuster cancer medicine Darzalex (daratumumab) is set to become the first injectable cancer treatment in Europe sui...
-
Drug approved for condition causing extreme hunger
The U.S. Food and Drug Administration (FDA) has for the first time approved a drug for acquired hypothalamic obesity, a condition marked by rapid weight gain dr...
-
New treatment recommended for children with brain tumours
The European Medicines Agency has recommended conditional approval of a new targeted treatment for children with the brain tumour pediatric low-grade glioma.
-
GSK eyes blockbuster potential – plans five new trials
GSK sees blockbuster potential in its experimental drug candidate Mo-rez. Early trial results suggest the treatment may shrink tumours in patients with advanced...
-
Astra Zeneca och GSK följer med Starmer till Kina – väntas stärka band
Läkemedelsbolagen Astra Zeneca och GSK ansluter till premiärminister Keir Starmers delegation till Kina denna vecka.
-
International medical graduates leave Sweden in high numbers
Three years after completing their studies, 46 percent of international doctoral students who graduated in the medical field had left the country. This is shown...
-
A healthy society requires more than a new pill
Sarah Lidé on how medicines are essential – but a sustainable approach to healthy societies also depends on prevention and behavioural change
-
Upcoming training: Introduction to ISO 15189:2022
Do you work with quality management in a medical laboratory? Don’t miss our ISO 15189:2022 online training course on May 12-13th — designed to help you understa...
-
Vaccine project targeting congenital infection scrapped in late-stage trial – “Clearly disappointed”
Hope for the first vaccine against the world’s most common congenital infection has taken a serious hit
-
Cinclus welcomes FDA announcement on single‑study requirement
Swedish Cinclus Pharma welcomes the signals from the United States that a single pivotal study, rather than two, may be sufficient when applying for market approval.
-
Breakthrough devices: Key insights from MDCG 2025-9 guidance
The Medical Device Coordination Group (MDCG) has published guidance MDCG 2025-9 to streamline the pathway for breakthrough devices (BtX) under the EU Medical De...
-
More than 150 jobs cut as Merck scales back vaccin production
Merck & Co, known as MSD in Europe, is hitting the brakes following a sharp decline in demand for its HPV vaccine Gardasil. Production at its facility in Durham...
BREAKING